Frank G.A.,Pa Herzen Moscow Oncology Research Institute |
Andreyeva Yu.Yu.,Pa Herzen Moscow Oncology Research Institute |
Vinogradov I.Yu.,Ryazan Clinical Oncology Dispensary |
Glatko S.B.,Omsk Clinical Oncology Dispensary |
And 6 more authors.
Arkhiv Patologii | Year: 2012
The paper analyzes 10 years' experience in HER2 status testing in breast cancer in Russia. The ASCO/CAP HER2 testing guidelines adaptable to the work of pathologists in Russia are considered.
Drui A.E.,Regional Childrens Hospital No 1 |
Drui A.E.,Ural Federal University |
Shorikov E.V.,Regional Childrens Hospital No 1 |
Shorikov E.V.,Institute of Medical Cell Technologies |
And 10 more authors.
Voprosy Onkologii | Year: 2015
Deletion of CDKN2A/pl6 gene located in the 9p21.3 region is common alteration for many types of cancer. It was described in neuroblastoma patients as well, while its prognostic significance is contradictory. The aim was to determine the epidemiology and prognostic impact of 9p deletion in neuroblastoma patients. 9p status was analyzed by MLPA in 100 tumor samples from primary neuroblastoma patients. Prognostic significance was estimated by overall (OS) and event-free survival (EFS) with median of follow-up time 28 months (range 1-166 months). 9p deletion was revealed in 8 (8.0%) patients, in 5 of them localized in 9p21-23 loci and in 3 involved only locus 9p21.3 (CDKN2A/pl6). Stage distribution was as follow: stage 1-2 patients, II-1, III-2, IV-3 and no patients with IVS stage. We didn't find any association of 9p deletion with clinical (stage, histological subtypes, age) or genetic (MYCN amplification (MNA), lp, llq deletions) risk factors. Presence of 9p deletion resulted in dramatic decreasing of survival rates: both EFS and OS were 0.00 vs. 0.60±0.06 and 0.68±0.06 correspondingly, p=0.035, p=0.014). Prognostic significance of this aberration retained in patients with localized neuroblastoma (EFS and OS 0.00 vs. 0.85±0.06 and 0.91±0.05 respectively, p=0.058, p=0.031) as well as in MYCN non-amplified patients (EFS and OS 0.00 vs. 0.68±0.06 and 0.75±0.06, p=0.047, p=0.017). In multivariate analysis of OS performed by stage, age, MNA, lp, 9p deletions and 17q gain as covariates patients with stage IV (p=0.042), MNA (p=0.049) and 9p deletion (p=0.041) had significantly poor survival. Thus 9p deletion involving CDKN2A/pl6 gene demonstrated strongly negative prognostic impact. Significance of this abnormality retains in favorable groups of patients with localized rumor and without MYCN amplification.
Zasadkevich Yu.M.,Ural Federal University |
Brilliant A.A.,Institute of Medical Cell Technologies |
Sazonov S.V.,Ural Federal University
Arkhiv Patologii | Year: 2015
The review gives data on the structure of cadherin cell adhesion molecules, their role in the body's development and malignant tumor progression. It describes cadherins that are considered to play the most important role in the development of a tumor process: E-, P-, and N-cadherins that belong to type I classical cadhedrins and VE-cadhedrin that does to type II cadherins. Particular emphasis is placed on the signal mechanisms with involvement of cadherins and cadherin-related molecules, which are realized in the body in health and in tumor transformation of cells.
Popov A.M.,Ural Federal University |
Shorikov E.V.,Regional Childrens Clinical Hospital No 1 |
Verzhbitskaya T.Yu.,Regional Childrens Clinical Hospital No 1 |
Tsaur G.A.,Regional Childrens Clinical Hospital No 1 |
And 4 more authors.
Voprosy Onkologii | Year: 2015
The purpose of the study was to evaluate the prognostic value of the detection of tumor cells in the bone marrow (BM) in children with neuroblastoma (NB) by flow cytometry. The detection of tumor cells was performed in BM of 51 patients with NB (24 boys and 27 girls) aged from 6 days to 15 years (median - 1 year 3 months). Flow cytometry allowed determining NB cells in BM in a much larger number of cases than cytomorphology (49.0 % and 29.4 % of patients, respectively). Patients, in whom NB cells were not detected in BM by flow cytometry, had significantly better event-free and overall survival rates as well as progression free survival (83, 5 %, 87, 7 % and 86, 8 %, respectively) compared with those in whom immunophenotyping revealed the tumor cells (28, 0 %, 35, 87 % and 34, 3 %, respectively). The prognostic value of the detection of BM lesion by flow cytometry was also confirmed in selected groups of patients with other criteria of stratification. Therefore the detection of tumor cells in BM by flow cytometry could potentially be considered in conjunction with other factors in choosing treatment strategy in patients with NB.
PubMed | Institute of Medical Cell Technologies, All India Institute of Medical Sciences and University of Nottingham
Type: | Journal: Scientific reports | Year: 2016
Granulocyte colony stimulating factor (G-CSF) may enhance recovery from stroke through neuroprotective mechanisms if administered early, or neurorepair if given later. Several small trials suggest administration is safe but effects on efficacy are unclear. We searched for randomised controlled trials (RCT) assessing G-CSF in patients with hyperacute, acute, subacute or chronic stroke, and asked Investigators to share individual patient data on baseline characteristics, stroke severity and type, end-of-trial modified Rankin Scale (mRS), Barthel Index, haematological parameters, serious adverse events and death. Multiple variable analyses were adjusted for age, sex, baseline severity and time-to-treatment. Individual patient data were obtained for 6 of 10 RCTs comprising 196 stroke patients (116 G-CSF, 80 placebo), mean age 67.1 (SD 12.9), 92% ischaemic, median NIHSS 10 (IQR 5-15), randomised 11 days (interquartile range IQR 4-238) post ictus; data from three commercial trials were not shared. G-CSF did not improve mRS (ordinal regression), odds ratio OR 1.12 (95% confidence interval 0.64 to 1.96, p=0.62). There were more patients with a serious adverse event in the G-CSF group (29.6% versus 7.5%, p=0.07) with no significant difference in all-cause mortality (G-CSF 11.2%, placebo 7.6%, p=0.4). Overall, G-CSF did not improve stroke outcome in this individual patient data meta-analysis.